143 related articles for article (PubMed ID: 2960533)
1. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
[TBL] [Abstract][Full Text] [Related]
2. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate S
Eur J Cancer Clin Oncol; 1984 Apr; 20(4):463-9. PubMed ID: 6233150
[TBL] [Abstract][Full Text] [Related]
3. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.
Dowsett M; Harris AL; Stuart-Harris R; Hill M; Cantwell BM; Smith IE; Jeffcoate SL
Br J Cancer; 1985 Oct; 52(4):525-9. PubMed ID: 2933050
[TBL] [Abstract][Full Text] [Related]
5. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.
Harris AL; Dowsett M; Smith IE; Jeffcoate SL
Br J Cancer; 1983 May; 47(5):621-7. PubMed ID: 6221746
[TBL] [Abstract][Full Text] [Related]
6. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; Smith IE
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
[TBL] [Abstract][Full Text] [Related]
7. Adrenal suppression with aminoglutethimide. III. Comparison of plasma delta 4- and delta 5-steroids in postmenopausal women treated for breast carcinoma.
Samojlik E; Santen RJ
J Clin Endocrinol Metab; 1978 Oct; 47(4):717-24. PubMed ID: 162517
[TBL] [Abstract][Full Text] [Related]
8. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.
Stuart-Harris R; Dowsett M; D'Souza A; Donaldson A; Harris AL; Jeffcoate SL; Smith IE
Clin Endocrinol (Oxf); 1985 Feb; 22(2):219-26. PubMed ID: 2985301
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of aminoglutethimide and danazol in the suppression of serum free oestradiol in breast cancer patients.
Dowsett M; Murray RM; Pitt P; Jeffcoate SL
Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1063-8. PubMed ID: 4065179
[TBL] [Abstract][Full Text] [Related]
10. Biochemical basis for the antagonism between aminoglutethimide and danazol in the endocrine treatment of breast cancer.
Dowsett M; Murray RM; Pitt P; Jeffcoate SL
Ann Clin Biochem; 1986 May; 23 ( Pt 3)():277-84. PubMed ID: 3789634
[TBL] [Abstract][Full Text] [Related]
11. Second line endocrine treatment of postmenopausal advanced breast cancer. Preliminary endocrine results of a 5-arm randomized phase II trial of medium vs low dose aminoglutethimide, with or without hydrocortisone vs hydrocortisone alone (EORTC 10861).
Bruning PF; Bonfrèr JM; Wildiers J; Jassem J; Beex LV; Schornagel J; Nooijen WJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1013-9. PubMed ID: 2149501
[TBL] [Abstract][Full Text] [Related]
12. The effects of low and high dose medroxyprogesterone acetate on sex steroids and sex hormone binding globulin in postmenopausal breast cancer patients.
Dowsett M; Lal A; Smith IE; Jeffcoate SL
Br J Cancer; 1987 Mar; 55(3):311-3. PubMed ID: 2952154
[TBL] [Abstract][Full Text] [Related]
13. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
14. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
Dowsett M; Harris AL; Smith IE; Jeffcoate SL
Br J Cancer; 1984 Sep; 50(3):357-61. PubMed ID: 6540595
[TBL] [Abstract][Full Text] [Related]
15. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause.
Stomati M; Monteleone P; Casarosa E; Quirici B; Puccetti S; Bernardi F; Genazzani AD; Rovati L; Luisi M; Genazzani AR
Gynecol Endocrinol; 2000 Oct; 14(5):342-63. PubMed ID: 11109974
[TBL] [Abstract][Full Text] [Related]
16. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.
Harris AL; Dowsett M; Jeffcoate SL; McKinna JA; Morgan M; Smith IE
J Clin Endocrinol Metab; 1982 Oct; 55(4):718-22. PubMed ID: 6213633
[TBL] [Abstract][Full Text] [Related]
17. Low-dose aminoglutethimide in postmenopausal breast cancer: effects on adrenal and thyroid hormone secretion.
Dowsett M; Mehta A; Cantwell BM; Harris AL
Eur J Cancer; 1991; 27(7):846-9. PubMed ID: 1657077
[TBL] [Abstract][Full Text] [Related]
18. Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Santen RJ; Samojlik E; Lipton A; Harvey H; Ruby EB; Wells SA; Kendall J
Cancer; 1977 Jun; 39(6 Suppl):2948-58. PubMed ID: 194681
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
MacNeill FA; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
[TBL] [Abstract][Full Text] [Related]
20. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer.
Bruning PF; Bonfrer JM; De Jong-Bakker M; Nooyen W
J Steroid Biochem; 1984 Sep; 21(3):293-8. PubMed ID: 6092781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
